Search

Displaying results 1091 - 1100 of 4344 in total
  1. Drug

    Valoctocogene roxaparvovec

    go.drugbank.com/drugs/DB15561
    ApprovedInvestigationalWithdrawn

    [L43292] Hemophilia A treatments such as prophylactic regimens of exogenous factor VIII or [emicizumab] improve the clinical outcomes of patients but do not eliminate breakthrough bleeding. … [L43282] The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active factor VIII in blood.

  2. Drug

    Coagulation factor X human

    go.drugbank.com/drugs/DB13148
    ApprovedInvestigational

    Coagulation Factor X (Human), is a plasma-derived human blood coagulation factor is used by adults and children (aged 12 years and above) with hereditary Factor X deficiency. … Coagulation Factor X (Human) solution is approved by the FDA for intravenous injection under the market name Coagadex which contains normally 100 IU/mL of coagulation Factor X derived from healthy donors

  3. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    Approved

    [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233]

  4. Drug

    Omalizumab

    go.drugbank.com/drugs/DB00043
    ApprovedInvestigational

    By binding to IgE and neutralizing it, omalizumab reduces free IgE levels and prevents IgE from binding to its receptors on immune cells.

  5. Drug

    Atidarsagene autotemcel

    go.drugbank.com/drugs/DB17538
    ApprovedInvestigational

    [L45191] Libmeldy was granted orphan designation by the EMA in April 2007, and was issued a marketing authorization in the EU in December 2020 for the treatment of certain manifestations of metachromatic

  6. Drug

    Stem bromelain

    go.drugbank.com/drugs/DB12249
    Approved

    This action allows bromelain to demonstrate a wide range of therapeutic benefits ranging from cardiovascular to anticancer therapy - but the specific mechanisms of action by which it can elicit these effects … The primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the

  7. Drug

    Niclosamide

    go.drugbank.com/drugs/DB06803
    ApprovedInvestigationalVet approved

    Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860]

  8. Drug

    Chlorpheniramine

    go.drugbank.com/drugs/DB01114
    ApprovedInvestigational

    A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less dr...

    Mixtures: CLORFENIRAMINA MALEATO 2MG+PSEUDOEFEDRINA SULFATO 30MG/5ML. JARABE, NOSTIL 75 MG/60MG/35MG BURUN SPREYİ, ÇÖZELTİ, 15 MLProducts: Chlortripolon Inj 10mg/ml, CHLORPYRIMINE INJECTION 10MG/ML
  9. Drug

    Pancuronium

    go.drugbank.com/drugs/DB01337
    Approved

    As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.

  10. Drug

    Colfosceril palmitate

    go.drugbank.com/drugs/DB09114
    ApprovedWithdrawn

    [T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990.[L1109] Nowadays colfosceril palmitate is under the state of canceled post-marketing.